- Home
- GH vs NUVL Comparison
GH vs NUVL Comparison
Compare GH & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GH
- NUVL
- Stock Information
- Founded
- GH 2011
- NUVL 2017
- Country
- GH United States
- NUVL United States
- Employees
- GH N/A
- NUVL N/A
- Industry
- GH Medical Specialities
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- GH Health Care
- NUVL Health Care
- Exchange
- GH Nasdaq
- NUVL Nasdaq
- Market Cap
- GH 5.5B
- NUVL 5.6B
- IPO Year
- GH 2018
- NUVL 2021
- Fundamental
- Price
- GH $41.72
- NUVL $69.85
- Analyst Decision
- GH Strong Buy
- NUVL Strong Buy
- Analyst Count
- GH 21
- NUVL 8
- Target Price
- GH $52.81
- NUVL $115.50
- AVG Volume (30 Days)
- GH 2.7M
- NUVL 625.4K
- Earning Date
- GH 04-30-2025
- NUVL 05-08-2025
- Dividend Yield
- GH N/A
- NUVL N/A
- EPS Growth
- GH N/A
- NUVL N/A
- EPS
- GH N/A
- NUVL N/A
- Revenue
- GH $773,996,000.00
- NUVL N/A
- Revenue This Year
- GH $19.53
- NUVL N/A
- Revenue Next Year
- GH $21.92
- NUVL N/A
- P/E Ratio
- GH N/A
- NUVL N/A
- Revenue Growth
- GH 28.20
- NUVL N/A
- 52 Week Low
- GH $18.01
- NUVL $55.54
- 52 Week High
- GH $52.92
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- GH 43.79
- NUVL 46.22
- Support Level
- GH $38.86
- NUVL $63.56
- Resistance Level
- GH $52.92
- NUVL $78.97
- Average True Range (ATR)
- GH 2.91
- NUVL 3.46
- MACD
- GH -0.74
- NUVL -0.38
- Stochastic Oscillator
- GH 20.34
- NUVL 40.84
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.